Tag: INTEGRILIN

Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint

WINNIPEG, MB, Nov. 4, 2021 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the results from the SAVI-PCI clinical trial demonstrating that the use of short infusion AGGRASTAT® (tirofiban hydrochloride) injection […]